DGAP-News: Inotrem SA: Inotrem Raises EUR18 million to Develop Innovative Sepsis Treatments in a Series A Financing Co-led by Edmond de Rothschild Investment Partners and Sofinnova Partners

| Source: EQS Group AG
DGAP-News: Inotrem SA / Key word(s): Capital Increase
Inotrem SA: Inotrem Raises EUR18 million to Develop Innovative Sepsis
Treatments in a Series A Financing Co-led by Edmond de Rothschild
Investment Partners and Sofinnova Partners

13.03.2014 / 19:00


Press Release

Inotrem Raises EUR18 million to Develop Innovative Sepsis Treatments in a
Series A Financing Co-led by Edmond de Rothschild Investment Partners and
Sofinnova Partners

Paris and Nancy, France, March 13 2014 - Inotrem S.A., a French biotech
company specialized in the control of immune reaction in acute inflammatory
diseases, announced today the completion of its Series A financing round.
With a total of EUR18 million, this round is the largest Series A round in
Europe this year. The round was co-led by leading international life
science venture capitalists Edmond de Rothschild Investment Partners and
Sofinnova Partners. Switzerland-based Biomed Invest and the French seed
investment firm Inserm Transfert Initiative also participated in the round.
Gilles Nobécourt of Edmond de Rothschild Investment Partners and Graziano
Seghezzi of Sofinnova Partners have joined the Supervisory Board of

Based on the pioneering research work of Prof. Sebastien Gibot, professor
of Critical Care Medicine at the University of Lorraine Medical School in
Nancy; and Dr. Marc Derive, co-founder and CSO of Inotrem, the company has
built a strong expertise around TREM-1, a pathway functioning as an
amplifier of the immune response cycle. TREM-1 is particularly up-regulated
in patients suffering from sepsis, an acute and severe infectious and
inflammatory syndrome which can lead to multiple organ failure and death.
Sepsis has an increasing incidence worldwide, affecting up to 1% of the
population annually with a mortality rate of 50%, placing sepsis as the
10th leading cause of death in developed countries. There are currently no
specific mechanistically targeted therapies approved for this indication
besides antibiotics and symptomatic agents.

Inotrem is developing an inhibitor of TREM-1 that has shown promising
activity in a very broad series of sepsis animal models. The company is
also working on a biomarker strategy to deliver a personalized healthcare
solution with the aim to identify patients who would most likely benefit
from the treatment.

This Series A round will support development of Inotrem's lead product
through late stage preclinical and early clinical trials in sepsis, plus
the characterization of its therapeutic potential in other inflammatory

Dr Jean-Jaques Garaud, CEO of Inotrem and formerly Head of Research and
Early Development at Roche, commented: "Our primary objective is to deliver
to the medical community novel treatments to help fight the dire
consequences of severe infections. Inotrem is developing one of the most
promising approaches to tackle such a devastating condition. We are very
proud and blessed to have now been recognized with the support of such a
strong investor syndicate."

For further information please contact
Dr. Jean-Jacques Garaud
+41 79 412 2897

For media inquiries:
MC Services AG
Raimund Gabriel
+49 89 210 228-30

About Inotrem
Created in 2013 by Prof. Sebastien Gibot, Dr. Marc Derive and Dr.
Jean-Jacques Garaud, Inotrem is a French biotech company specializing in
the discovery and development of novel treatments in the field of
inflammatory pathologies with a focus on critical care. The Company's
leading product candidate is a TREM-1 inhibitor that aims to control
excessive inflammation in severe sepsis patients. Since its inception
Inotrem has received the initial support of the Incubateur Lorrain and the
University of Lorraine in Nancy, Région Lorraine, BPI France and Inserm

About Edmond de Rothschild Investment Partners
Paris-based Edmond de Rothschild Investment Partners is the private equity
affiliate of the Edmond de Rothschild Group, which is specialized in asset
management and private banking. Edmond de Rothschild Investment Partners is
dedicated to minority investments into privately-owned companies. It has
currently close to EUR1 billion under management which is being invested
primarily as life sciences venture capital and growth capital. Its Life
Sciences Team of eight professionals brings together over 60 years of
experience in the Life Science industry and more than 100 years of private
equity and venture capital experience. The team has raised over EUR450
million through its Biodiscovery franchise and is currently investing
BioDiscovery 4. For more information please visit: www.edrip.fr

About Sofinnova Partners 
Sofinnova Partners is an independent venture capital firm based in Paris,
France. For 40 years, the firm has backed nearly 500 companies at different
stages of their development - pure creations, spin-offs, as well as
turnaround situations - and worked alongside Europe's key entrepreneurs in
the Life Sciences industry. With EUR1.3 billion of funds under management,
Sofinnova Partners has created market leaders with its experienced team and
hands-on approach in building portfolio companies through to exit. For more
information please visit: www.sofinnova.fr

About Biomed Invest
BioMedPartners AG is an independent healthcare-dedicated investment firm
based in Basel, Switzerland, that provides private equity and mezzanine
financing to private early- to mid-stage healthcare and life science
companies in Switzerland and neighboring regions (Alpine Rim).
BioMedPartners have invested in over 40 companies. BioMedPartners currently
invest out of their BioMedInvest II LP fund, which has a size of CHF 106
million, and was closed in 2009. For more information please visit:

About Inserm Transfert Initiative 
Inserm Transfert Initiative is a life sciences seed investment firm based
in Paris, France, linked to the French National Institute of Health and
Medical Research (Inserm). Inserm Transfert Initiative focuses its
investments in companies coming from public research laboratories. Inserm
Transfert Initiative managed EUR39M and is supported by Inserm, BPI France
(through the FNA funds), top tiers pharmaceutical companies and an
insurance company. Inserm Transfert Initiative has invested in over 20
companies since 2001. For more information please visit:

End of Corporate News


13.03.2014 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de


257431 13.03.2014